| Literature DB >> 30155375 |
Ghulam M Kaimkhani1, Adeel A Siddiqui1, Nusrat Rasheed2, Mohammad Irfan Rajput2, Jagdesh Kumar2, Mohammad Hassan Khan2, Shahzadi Nisar2, Sheema Mustafa3, Uzair Yaqoob4.
Abstract
Diabetes mellitus is a universal health problem, with its prevalence in Pakistan making it among the top 10 countries in the world. Approximately 13.9 million people in Pakistan will have developed diabetes by 2030. Diabetic foot ulcer (DFU) is one of the more serious complications of diabetes. If not treated properly, patients may develop diabetic foot osteomyelitis leading to gangrene and amputation. These infections are usually polymicrobial, with Staphylococcus aureus (S. aureus), Proteus, Pseudomonas, and Escherichia coli (E. coli) being among the more common organisms isolated from DFU. This survey of patients with DFU in a tertiary hospital in Karachi, Pakistan found 68.5% of patients had peripheral neuropathy, 57% had chronic osteomyelitis, and 37% and 49% had Wagner grades 2 and 3, respectively. Infections were polymicrobial in 83% of patients, E. coli was isolated from 63%, and S. aureus from 58%. Of the isolated organisms, 95% were sensitive to meropenem and 81% to linezolid.Entities:
Keywords: diabetic foot ulcer; diabetic osteomyelitis; polymicrobial infection
Year: 2018 PMID: 30155375 PMCID: PMC6110415 DOI: 10.7759/cureus.2872
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Comorbidities Associated with Diabetic Foot Ulcers
| Associated Medical Problems | Frequency | Percentage |
| None | 1 | 1% |
| Smoking alone | 4 | 4% |
| Obesity alone | 2 | 2% |
| Hyperlipidemia alone | 18 | 18% |
| Hypertension (HTN) alone | 44 | 44% |
| Ischemic heart disease (IHD) alone | 3 | 3% |
| Smoking + HTN + IHD | 12 | 12% |
| Smoking + HTN | 16 | 16% |
Severity of Ulcers, As Determined by Wagner Grade, in Patients with Diabetic Foot Ulcer
| Grade | 0 | 1 | 2 | 3 | 4 | 5 | Total |
| Patients (%) | 0 (0%) | 0 (0%) | 37 (37%) | 49 (49%) | 12 (12%) | 2 (2%) | 100 |
Distributions of Microorganism Isolated from Ulcer Samples
| Organism | Frequency | Percentage | Frequency as Monomicrobial | Percentage as Monomicrobial | Frequency as Polymicrobial | Percentage as Polymicrobial |
| Escherichia coli | 63 | 63.0 | 3 | 17.6 | 60 | 72.3 |
| Staphylococcus aureus | 58 | 58.0 | 1 | 5.9 | 57 | 68.7 |
| Pseudomonas aeruginosa | 37 | 37.0 | 0 | 0 | 37 | 44.6 |
| Streptococcus pyogenes | 42 | 42.0 | 1 | 5.9 | 41 | 49.4 |
| Streptococcus epidermatitis | 14 | 14.0 | 0 | 0 | 14 | 16.9 |
| Streptococcus pneumoniae | 0 | 0.0 | 0 | 0 | 0 | 0 |
| Klebsiella pneumoniae | 43 | 43.0 | 0 | 0 | 43 | 51.8 |
| Proteus mirabilis | 31 | 31.0 | 2 | 11.8 | 29 | 34.9 |
| Enterococcus | 40 | 40.0 | 8 | 20.0 | 32 | 80.0 |
Antibiotic Sensitivity of Gram-positive Organisms Isolated from Diabetic Foot Ulcers
| Antibiotic | Enterococcus | Staphylococcus aureus | Streptococcus pyogenes | Streptococcus epidermis | Streptococcus pneumoniae |
| Amikacin | 72.5% | 65.5% | 50% | 35.7% | 64% |
| Amoxicillin | 67.5% | 39.7% | 28.6% | 28.6% | 48% |
| Aztreonam | 77.5% | 51.7% | 42.9% | 57.1% | 62% |
| Cefixime | 55% | 29.3% | 16.7% | 42.9% | 45% |
| Ceftriaxone | 57.5% | 29.3% | 14.3% | 71.4% | 45% |
| Cefuroxime | 72.5% | 34.5% | 21.4% | 85.7% | 55% |
| Piperacillin Tazobactam | 92.5% | 60.3% | 52.4% | 78.6% | 75% |
| Fucidic acid | 42.5% | 43.1% | 61.9% | 50% | 46% |
| Ciprofloxacin | 37.5% | 43.1% | 61.9% | 57.1% | 50% |
| Linezolid | 85% | 82.8% | 73.8% | 57.1% | 81% |
| Erythromycin | 70% | 86.2% | 88.1% | 71.4% | 81% |
| Meropenem | 95% | 93.1% | 90.5% | 78.6% | 93% |
| Metronidazole | 80% | 72.4% | 61.9 | 64.3% | 73% |
Antibiotic Sensitivity of Gram-negative Organisms Isolated from Diabetic Foot Ulcers
| Antibiotic | Klebsiella | Proteus | Escherichia coli | Pseudomonas aeruginosa | Enterococcus | Staphylococcus aureus | Streptococcus epidermis |
| Amikacin | 62.8% | 48.1% | 60.3% | 45.9% | 72.5% | 65.5% | 35.7% |
| Aztreonam | 58.1% | 38.7% | 55.6% | 43.2% | 77.5% | 51.7% | 57.1% |
| Cefixime | 46.5% | 9.7% | 39.7% | 16.2% | 55% | 29.3% | 42.9% |
| Ceftriaxone | 51.2% | 29.0% | 39.7% | 24.3% | 57.5% | 29.3% | 71.4% |
| Cefuroxime | 60.5% | 32.3% | 50.8% | 24.3% | 72.5% | 34.5% | 85.7% |
| Piperacillin Tazobactam | 79.1% | 74.2% | 68.3% | 62.2% | 92.5% | 60.3% | 78.6% |
| Fucidic acid | 37.2% | 51.6% | 38.1% | 51.4% | 42.5% | 43.1% | 50% |
| Ciprofloxacin | 44.2% | 58.1% | 49.2% | 51.4% | 37.5% | 43.1% | 57.1% |
| Linezolid | 72.1% | 54.8% | 79.4% | 70.3% | 85% | 82.8% | 57.1% |
| Erythromycin | 65.1% | 58.1% | 68.3% | 78.4% | 70% | 86.2% | 71.4% |
| Meropenem | 93% | 93.5% | 90.5% | 86.5% | 95% | 93.1% | 78.6% |
| Metronidazole | 67.4% | 61.3% | 71.4% | 62.2% | 80% | 72.4% | 64.3% |